Skip to main content
WHANIN PHARM CO.,LTD logo

WHANIN PHARM CO.,LTD — Investor Relations & Filings

Ticker · 016580 ISIN · KR7016580003 KO Manufacturing
Open in API
Filings indexed 179 across all filing types
Latest filing 2019-04-29 Earnings Release
Country KR South Korea
Listing KO 016580

About WHANIN PHARM CO.,LTD

https://www.whanin.com/?lang=eng

WHANIN PHARM CO.,LTD. is a pharmaceutical company that develops, manufactures, and sells a range of therapeutic products. The company specializes in medications for the Central Nervous System (CNS), with a particular focus on neuropsychiatric treatments such as anti-psychotics and CNS stimulants. In addition to its core CNS portfolio, Whanin Pharm's product line includes pharmaceuticals for the cardiovascular and gastrointestinal systems, antibiotics, and vitamin supplements. The company also provides development and manufacturing services for finished drug formulations.

Recent filings

Filing Released Lang Actions
연결재무제표기준영업(잠정)실적(공정공시)
Earnings Release Classification · 100% confidence The document is a 'Provisional Earnings Report' (영업(잠정)실적) for Hwanin Pharmaceutical. It provides key financial highlights (revenue, operating profit, net income) for the first quarter of 2019 compared to previous periods. This is a standard initial announcement of quarterly financial results, which fits the definition of an Earnings Release (ER). Q1 2019
2019-04-29 Korean
투자판단관련주요경영사항(특허권 취득)
Regulatory Filings Classification · 95% confidence The document is a regulatory disclosure from Hwanin Pharmaceutical regarding the acquisition of a patent. It follows the standard format for 'Major Management Matters' (투자판단 관련 주요경영사항) in the Korean market, which is a specific type of regulatory filing. Since it does not fit into categories like financial reports, board changes, or dividends, it falls under the general regulatory filing category.
2019-04-03 Korean
사업보고서 (2018.12)
Annual Report Classification · 100% confidence The document is a 'Business Report' (사업보고서) for Whan In Pharm. Co., Ltd. (환인제약) for the fiscal year 2018 (January 1, 2018, to December 31, 2018). It contains comprehensive financial statements, management discussion and analysis, governance information, and auditor opinions, which are the defining characteristics of a 10-K (Annual Report) in the Korean regulatory context (DART system). FY 2018
2019-03-29 Korean
정기주주총회결과
Declaration of Voting Results & Voting Rights Announcements Classification · 100% confidence The document is titled '정기주주총회결과' (Annual General Meeting Results) and provides a detailed breakdown of the resolutions passed during the meeting, including financial statement approval, dividend declarations, and board/director appointments. This fits the definition of a Declaration of Voting Results & Voting Rights Announcement (DVA), as it reports the official outcomes of shareholder votes at an AGM.
2019-03-22 Korean
사외이사의선임ㆍ해임또는중도퇴임에관한신고
Board/Management Information Classification · 100% confidence The document is a regulatory filing submitted to the Financial Services Commission/Korea Exchange regarding the appointment or resignation of an outside director (사외이사의 선임ㆍ해임 또는 중도퇴임에 관한 신고). This falls under the category of board management changes, specifically the appointment of a director.
2019-03-22 Korean
감사보고서제출
Audit Report / Information Classification · 98% confidence The document is a formal notification of the submission of an audit report ('감사보고서 제출') by Hwanin Pharmaceutical. It provides a summary of the audit opinion ('적정' - unqualified) and key financial data for the fiscal year ending 2018-12-31. Since this is a standalone notification regarding the filing of an audit report rather than the full annual report or a general regulatory announcement, it fits the 'Audit Report / Information' category. FY 2018
2019-03-14 Korean

Browse filings by year

9 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.